Calcium is one of the ions that move across the cellular membrane during cardiac contraction and relaxation. The primary use of calcium channel blockers in ACLS is for the treatment of stable, narrow complex tachycardias refractory to Adenosine and to lower the blood pressure of ischemic stroke patients with severe hypertension. Use of calcium channel blockers for SVT refractory to Adenosine and A-Fib or A-Flutter with RVR. Contraindications of calcium channel blockers. Nicardipine use during the treatment of ischemic strokes. For more information on ACLS medications check out the pod resource page at passacls.com. **American Cancer Society (ACS) Fundraiser This is the fourth year that I'm participating in Real Men Wear Pink to increase breast cancer awareness and raise money for the American Cancer Society's life-saving mission. I hope you'll consider contributing. Every donation makes a difference in the fight against breast cancer! http://main.acsevents.org/goto/paultaylor (Paul Taylor's ACS Fundraiser) THANK YOU! Connect with me: Website: https://passacls.com (https://passacls.com) https://twitter.com/PassACLS (@PassACLS) on Twitter https://www.linkedin.com/company/pass-acls-podcast/ (@Pass-ACLS-Podcast) on LinkedIn Good luck with your ACLS class!
In atrial fibrillation (A-Fib) and atrial flutter (A-Flutter) the electrical impulse for cardiac contraction is in the atria but isn't the normal pacemaker of the heart, the SA node. The ECG characteristics of A-Fib and A-Flutter. Recognition and treatment of unstable patients in A-Fib/Flutter with rapid ventricular response (RVR). Team safety when cardioverting an unstable patient in A-FIB. Adenosine's role for stable SVT patients with atrial rhythms. Treatment of stable patients in A-Fib/Flutter with RVR. **American Cancer Society (ACS) Fundraiser This is the fourth year that I'm participating in Real Men Wear Pink to increase breast cancer awareness and raise money for the American Cancer Society's life-saving mission. I hope you'll consider contributing. Every donation makes a difference in the fight against breast cancer! http://main.acsevents.org/goto/paultaylor (Paul Taylor's ACS Fundraiser) THANK YOU! Connect with me: Website: https://passacls.com (https://passacls.com) https://twitter.com/PassACLS (@PassACLS) on Twitter https://www.linkedin.com/company/pass-acls-podcast/ (@Pass-ACLS-Podcast) on LinkedIn Good luck with your ACLS class!
Canelo, regresara hasta el siguiente año, el emxicano aun o sabe si se operara!Saul Alvarez presume su recta en la apertura de la temporada de lso charros!Sebastian Fundora vence sin convencer!!Wilder regresa el fin de semana!!
Angie Dodge suffered a terrible fate in the hands of her killer. As one of the cold cases of the 20th century, the investigation led to a false accusation. The wrongly identified culprit unfortunately spent 20 years in prison before the authorities finally traced the real perpetrator. Because of an intense DNA matching technology and the convict's confession, the case was finally solved. In the second part of the two-episode interview with Tom Myers, discussions about the importance of interviews and interrogations were brought up. In a world where crimes continue to plague people, it's up to the authorities to be extra vigilant and discerning when it comes to their investigation. Liars can hide really well but authorities should know how to identify them. Technology paves the way for accuracy. Equipment that analyze genetics can trace the culprit. Skills of probing are also integral in identifying the suspect. “You can't expect to be in a bad situation and come out of that okay. You wouldn't be swimming with sharks that are really hungry.” - Tom MyersThree TakeawaysBe prepared in interviewing people involved in a crime. Database systems help narrow down the culprits of crimes. Technology continues to innovate and helps resolve investigations.In this Episode0:00 Introduction0:37 The importance of preparation7:08 Ideal environment for interviews10:08 How to indicate planned crimes16:31 The Idaho case18:26 Social conventions have changed. Resources:Check out M-Vac here: https://www.m-vac.com/ All Things Crime is a new, comprehensive video series that will explore every aspect of crime and the ensuing investigation, one video interview at a time. The host, Jared Bradley, is the President of M-Vac Systems, which is a wet-vacuum based forensic DNA collection system, and has experience traveling the world training all levels of law enforcement and crime lab DNA analysts in using the M-Vac to help solve crime.Along the way he has met people from all walks of life and experience in investigating crimes, so is putting that knowledge to use in another way by sharing it in these videos. If you are interested in more videos about the M-Vac, DNA and investigations, also check out the M-Vac's channel @https://www.youtube.com/c/MVacSystems...
In Season 3, Episode 6, Roger Green assembles audio clips from Surfing the NASH Tsunami's coverage of NASH-TAG 2022 to reveal an evolving view of the role combination therapies will play in the treatment and management of NASH patients. Discussion about “combination therapies” typically focuses on the idea of multiple agents prescribed concurrently to address a medical condition when monotherapy will not achieve desired goals. At NASH-TAG 2022, the concept of combination therapies took some interesting directions:Longitudinal drug combinations — initial intervention designed to cause a fast reversal of fibrosis or defatting of the liver, followed by a longer-term therapy (mono or combination, but not with the first-round agent) designed to provide longer-term, more complete metabolic benefits in a regimen that is safer, more tolerable, less expensive, or some combination of these.Longitudinal diagnostics — an early, inexpensive “rule out” test like FIB-4, followed by a liquid or machine-based test that provides more accurate disease staging.Logical combinations — so far, most drug combination trials have resulted from a manufacturer trying to resuscitate a developmental agent that missed endpoints in monotherapy trials. It would be more logical to design combinations based on complementary modes of action.This episode explores these and other combination therapy issues using quotes from the NASH-TAG 2022 coverage and Roger's commentary.
Chapter 12, and Crunchy wants a cup of tea and a marmite sandwich. How does he come up with these wacky ideas? X, Squared - the latest audiobook novel by Daniel's Nemesis, follows nervous young wreck Crunchy as he begins work experience at the mysterious organisation The FIB. Things soon decline into a world inspired by German Expressionism and early 2000s Japanese Horror movies. It's a hoot! (Please forgive the accents!) There are separate episodes where I give analysis and discussion about the chapters. Check out the feed for those catch-up episodes. One has already been released to explain the origins of the novel. YouTube channel with full episodes, just the chapters, and podcast highlights: https://www.youtube.com/channel/UCz2-GH1Zuc9He6NKtwr1CeQ What are your thoughts on this and previous chapters? Tell me your thoughts at email@example.com You can also find me on Twitter to know when a new episode is released at @DanielsNemesis, though nothing much happens there.
Today, we share a modern-day story of David and Goliath with Dr. Baxter Montgomery. In 1997, Dr. Montgomery opened Montgomery Heart and Wellness in Houston, Texas right in the shadows of the powerful and world-renowned campus of the Texas Medical Center, the world's largest medical center. As a board-certified cardiologist and cardiac electrophysiologist, Dr. Montgomery has treated thousands of patients with severe cardiovascular diseases, but he started to notice something. Even though he employed state-of-the-art procedures, interventions, ablations, and medications, his patients continued to grow weaker and sicker. Montgomery, instead, started researching nutrition's role in disease reversal and found that - you guessed it- PLANTS were the common denominator in determining wellness. Today at Montgomery Heart and Wellness, Dr. Montgomery helps patients achieve optimal health and wellness through various nutrition programs. His goal? To get his patients to think beyond the script, improve their health, and reverse these chronic lifestyle diseases. He truly is a modern-day David fighting a giant Goliath medical system, but much like David, he's ready, willing, and able to slay the dragon of lifestyle disease. Episode Timestamps 6:00 Why he was inspired to take a different approach to medicine 12:45 His own personal journey back to health that inspired his nutrition protocols 16:45 Just do this for seven days! 22:50 The results are astounding 24:30 Changing the Health Care Paradigm - “Heart and Souls of a Champion” upcoming program 29:50 Is his facility and in-patient center? 31:20 What's an LVAT? 32:40 What is Lipoprotein a? 35:00 Are his colleagues on board, or still resistant? 39:00 Dr. Montgomery's 3 pillars of optimal health 41:50 How can the human body heal itself so quickly? 45:35 Moderation is like running through quicksand. 47:40 How do his patients respond to his protocols and advice? 49:00 Why does he prescribe raw foods only for his patients? 57:00 All about the upcoming four-day Open House and Red Carpet Gala 1:02:00 How he is living his God-given passion 1:05:00 Bonus - Dr. Montgomery's take on A-Fib and PVCs Episode Resources Episode Webpage Watch the Episode on YouTube Montgomery Heart and Wellness Website Learn More About Montgomery Heart Open House and Gala - October 19th-22nd, 2022 To stock up on the best-tasting, most convenient, 100% PLANTSTRONG foods, including our broths and soups, check out all of our PLANTSTRONG products HERE. Give us a like on the PLANTSTRONG Facebook Page and check out what being PLANSTRONG is all about. We always keep it stocked full of new content and updates, tips for healthy living, delicious recipes, and you can even catch me LIVE on there! We've also got an Instagram! Check us out and share your favorite PLANTSTRONG products and why you love it! Don't forget to tag us using #goplantstrong
Jackie Nava se retira con Triunfo!Luis Nery pasa el tramite!Davis v Garcia hasta el proximo añoBom arum se reune con Canelo team!!Fundora por una victoria mas que lo acerque al titulo abosluto de los super welter!
A-Block (1:46) SPECIAL COMMENT: Trump threatens violence against Mitch McConnell and Marjorie Trailer Park Greene implies Republicans should kill Democrats but the real sign over the weekend that the GOP has transformed entirely into a nihilist mob is neither of them (2:44) It's Susan "I Haven't Learned My Lesson" Collins, who has just noticed that "a Senator or House member (might be) killed." (8:30) It is the Collinses of this nation who have let Trump echo his cultists' call for Civil War by valuing their own offices and power more than they do the nation. B-Block (13:53) EVERY DOG HAS ITS DAY: Stella in St. Louis (14:58) POSTSCRIPTS TO THE NEWS: Brazil's Burn The Amazon vote goes to a runoff; they've identified the DeSantis Trafficking Coyote; Prime Minister Truss attacks the King; Trailer Park Greene self-owns. (17:37) IN SPORTS: Aaron Judge now has one homer in his last 49 plate appearances; Angels sign Ohtani - to trade him? T.J. Watt beats Fox to an exclusive about his A-Fib and they'll close a loophole to keep future Tuas on the bench. (21:18) THE WORST PERSONS IN THE WORLD: Michigan's Tudor Dixon (WHO THE HELL IS NAMED 'TUDOR') competes with Conservative unemployables Sophie Corcoran and Alex Bruesewitz (whose entry is one of the most despicable public statements I've ever covered). C-Block (28:25) THINGS I PROMISED NOT TO TELL: It's the anniversary of the week David Letterman revealed, on his show, that he was being blackmailed. Incredibly, I WORKED WITH the blackmailer 40 years ago at CNN, and somehow I also worked with the other victim when the Trumpists tried to blackmail Jeff Bezos!See omnystudio.com/listener for privacy information.
(0:00) Arcand previews Patriots/Packers (16:35) Tom King from the Nashua Telegraph joins the Service (34:54) JJ Watt shared a tweet earlier about going through A Fib, getting shocked back into rhythm and plans to play today
(0:00) Arcand previews Patriots/Packers (16:35) Tom King from the Nashua Telegraph joins the Service (34:54) JJ Watt shared a tweet earlier about going through A Fib, getting shocked back into rhythm and plans to play today
After a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will shape the next 6-12 months in Fatty Liver disease. This conversation explores the role of multiple biomarker tests in the diagnostic process and how these might vary in the panelists' home countries.To begin, Louise notes that in the UK, many primary care physicians do not perform even basic liver tests, making it impossible to compute FIB-4. Roger questions whether publicizing of guidelines like the AACE or EASL guidelines will speed uptake of FIB-4. The guidelines recommend that front-line physicians not screen their T2DM patients for NAFLD, since 80+% will test positive. Instead, they recommend using a FIB-4 test to identify patients at risk due to current fibrosis. Roger then asks whether these guidelines will move into actual practice. Louise and Jörn each note that in their countries, front-line professionals are not required to perform liver enzyme blood work. Yet, these tests are pivotal for early liver screening. Louise doubts that change will come until after an expensive drug is approved, at which point there will be economic motivation to test. Jörn is more hopeful that with simple tests, he and other hepatologists can educate endocrinologist colleagues on the reasons to adopt this testing strategy over time.As the conversation wraps up, Jörn begins to segue from the future of care pathways to the exciting future of drug development.
Shakur Stevenson deja titulo de las 130 lbs en la bascula!Floy Mayweather noquea a pupilo artemacialista de Pacquiao!!Amanda Serrano regresa con victoria y va por titulo ante Mexicana!Jackie Nava se va del boxeo tras mas de 20 años como profesional!
The last month has witnessed several major Fatty Liver conferences and others that touch on NAFLD in the context of metabolic disease. One common theme has been the need for different specialties to align in treating the complete range of non-communicable metabolic diseases. In this episode, Roger Green, Jörn Schattenberg and Louise Campbell propose factors that have the potential to dramatically shift the force around fatty liver disease over the next six months.Jörn starts the conversation with a personal example of a larger trend: he attended last month's EASD meeting for the first time. Historically, few hepatologists attend this meeting, but Jörn believes his attendance is indicative of a trend: hepatologists and endocrinologists working together on diabetes and NAFLD. Louise echoes the sentiment that liver health is gaining traction as a critical function of holistic patient management, although cardiology appears to be slow on the uptake.Roger links this collaborative energy to a completely different kind of energy formation: capital investment. He notes Akero's recent filing for $230 million in equity to help bring efruifermin to market based on Phase 2b results. If this effort succeeds, Roger suggests that it may signify that the financial markets are becoming more optimistic about NASH drugs after several years of extreme skepticism.Next, Jörn returns to his original theme to discuss how endocrinologists have received the concept of liver disease as part of multimorbidity management in patients living with T2DM. He reports that endocrinologists have been enthusiastic about the idea and eager to learn the liver testing tools and metrics they should use.The group then responds to the AACE guidelines promoted last May. The guidelines recommend that front-line physicians not screen their T2DM patients for NAFLD, since 80+% will test positive. Instead, guidelines recommend using a FIB-4 test to identify patients at risk due to current fibrosis. Roger asks whether these will move into actual practice. Louise and Jörn each state that in their countries, front-line treaters are not required to perform liver enzyme blood work. These tests are pivotal for early liver screening. Louise doubts that change will come until after an expensive drug is approved, at which point there will be economic motivation to test. Jörn is more hopeful that with simple tests, he and other hepatologists can educate endocrinologist colleagues on the reasons to adopt this testing strategy over time.The conversation shifts to speculation as to whether prescribers or payers will be the source of bottleneck in patient care pathways at the outset of a drug approval. The group generally agrees that pushback will come from the payers and that healthcare systems are not yet ready. They then look towards the social and political will to take action on the crisis. In response to Roger's question, the group acknowledges the immense hurdles present in changing provider behavior over the next 6-12 months while stressing the importance of provider education and patient empowerment.Finally, the group discusses the future of the recently coined “combo-combo world,” where correct diagnosis will require a combination of biomarker tests and treatment may require a combination of therapies. At the end, Roger asks what changes each member envisions. Surf on to find out.
Patients with a narrow complex tachycardia with a rate over 150 BPM are in SVT. Unstable patients in SVT, or V-Tach with a pulse, should be cardioverted with a synchronized shock. Assessment & treatment of stable tachycardic patients. Commonly used vagal techniques. A less common technique to stimulate the vagus nerve is the dive reflex. Indications and use of Adenosine for stable patients in SVT refractory to vagal maneuvers. Possible treatments for patients found to be in A-Fib or A-Flutter with RVR after administration of Adenosine. Carotid sinus massage. Additional medical podcasts that have episodes on tachycardia can be found on the pod resources page at passacls.com. **American Cancer Society (ACS) Fundraiser This is the fourth year that I'm participating in Real Men Wear Pink to increase breast cancer awareness and raise money for the American Cancer Society's life-saving mission. I hope you'll consider contributing. Every donation makes a difference in the fight against breast cancer! http://main.acsevents.org/goto/paultaylor (Paul Taylor's ACS Fundraiser) THANK YOU! Connect with me: Website: https://passacls.com (https://passacls.com) https://twitter.com/PassACLS (@PassACLS) on Twitter https://www.linkedin.com/company/pass-acls-podcast/ (@Pass-ACLS-Podcast) on LinkedIn Good luck with your ACLS class!
Today, we talk about what it would be like if the Fib from Outer Space was real. How would little miss LBF go about having a giant space alien cause havoc in her town? What if the Fib had a secret lair here on Earth? How would LBF and friends do if they encountered the Fib? So many questions and more on this episode of the LBF Podcast! FIB INTERACTIVE LIVESTREAM: https://youtu.be/7-picOy011g "How To Sound Like Fib!!!" VIDEO: https://youtu.be/LsQSsxM0erA SUPPORT THE PODCAST HERE: https://anchor.fm/larryboyfanatic/support PATREON: https://www.patreon.com/larryboyfanatic REDBUBBLE: https://ronniegonza500.redbubble.com --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/larryboyfanatic/message Support this podcast: https://anchor.fm/larryboyfanatic/support
Chapter 11, and finding themselves in some real trouble, it's time for Crunchy to save the gang again! Oh, Crunchy, how do you do it? X, Squared - the latest audiobook novel by Daniel's Nemesis, follows nervous young wreck Crunchy as he begins work experience at the mysterious organisation The FIB. Things soon decline into a world inspired by German Expressionism and early 2000s Japanese Horror movies. It's a hoot! (Please forgive the accents!) There are separate episodes where I give analysis and discussion about the chapters. Check out the feed for those catch-up episodes. One has already been released to explain the origins of the novel. YouTube channel with full episodes, just the chapters, and podcast highlights: https://www.youtube.com/channel/UCz2-GH1Zuc9He6NKtwr1CeQ What are your thoughts on this and previous chapters? Have you spotted something that I have missed? Tell me your thoughts at firstname.lastname@example.org You can also find me on Twitter to know when a new episode is released at @DanielsNemesis, though nothing much happens there.
Radiative transfer in stars by feebly interacting bosons by Andrea Caputo et al. on Monday 19 September Starting from first principles, we study radiative transfer by new feebly-interacting bosons (FIBs) such as axions, axion-like particles (ALPs), dark photons, and others. Our key simplification is to include only boson emission or absorption (including decay), but not scattering between different modes of the radiation field. Based on a given distribution of temperature and FIB absorption rate in a star, we derive explicit volume-integral expressions for the boson luminosity, reaching from the free-streaming to the strong-trapping limit. The latter is seen explicitly to correspond to quasi-thermal emission from a "FIB sphere" according to the Stefan-Boltzmann law. Our results supersede expressions and approximations found in the recent literature on FIB emission from a supernova core and, for radiatively unstable FIBs, provide explicit expressions for the nonlocal ("ballistic") transfer of energy recently discussed in horizontal-branch stars. arXiv: http://arxiv.org/abs/http://arxiv.org/abs/2204.11862v2
Adenosine is the first IV medication given to stable patients with sustained supraventricular tachycardia (SVT) refractory to vagal maneuvers. Common causes of tachycardia. Symptoms indicating a stable vs unstable patient. Cardiac effects of Adenosine. Indications for the use of Adenosine in the ACLS Tachycardia algorithm. Considerations and contraindications for Adenosine use. Adenosine as a diagnostic for patients in A-Fib or A-Flutter with RVR. Dosing and administration of Adenosine. Other podcasts that cover common ACLS antiarrhythmics in detail. **American Cancer Society (ACS) Fundraiser This is the fourth year that I'm participating in Real Men Wear Pink to increase breast cancer awareness and raise money for the American Cancer Society's life-saving mission. I hope you'll consider contributing. Every donation makes a difference in the fight against breast cancer! http://main.acsevents.org/goto/paultaylor (Paul Taylor's ACS Fundraiser) THANK YOU! Connect with me: Website: https://passacls.com (https://passacls.com) https://twitter.com/PassACLS (@PassACLS) on Twitter https://www.linkedin.com/company/pass-acls-podcast/ (@Pass-ACLS-Podcast) on LinkedIn Good luck with your ACLS class!
In this episode, the group covers the Day Two program and offers final thoughts on the Paris NASH 2022 review.The conversation starts with Louise introducing the discussion around estrogen replacement therapy and fatty liver in post-menopausal women. She notes this an area of opportunity for improving women's health.Next, Arun Sanyal's science lecture on NITs is discussed. The lecture is noted to be less about groundbreaking science and more so a clear description of the thinking behind developing an NIT diagnostic pathway. This pathway starts with FIB-4 and goes into more accurate (and expensive) tests for patients that FIB-4 does not rule out.From there, the conversation shifts to one last discussion about the ways that liver disease is central in the cluster of chronic non-communicable metabolic diseases. Finally, Roger offers the closing question. Each responds with their feelings toward the future of NASH, NAFLD, metabolic disease, and interdisciplinary collaboration.Listen on for the Surfer's, and Jeff McIntyre's, final thoughts on Paris NASH 2022.
No- seriously, the week in the rockies as FABULOUS! Blind Hog and Acorn both lost like 5-6 lbs, crazy good hiking days and wonderful lodgings. Airports were "interesting" to say the least. Missed one connecting flight by minutes, but truly that only set the holiday back by 4 hours- big whoop. At least the luggage did not get lost~Three nights on the Icefields Parkway, three nights at Glacier. Packed it in and could easily have made it a week in each place. Things to look forward to in the future- a return trip to the Icefields!Blind Hog and Acorn tested for the 'Rona the day before the trip and the morning after returning. Negative and negative. Wednesday night Blind Hog had a hard time sleeping and Thursday he was not feeling well, chalked it up to the A-Fib but when he complained of "being cold," his temp read 99.1. Another covid test popped positive before the solution crossed the control line! Acorn tested positive 2 days later... We see this... Least she does not have to wear an N-95 mask in the house all day!So, imagine ragweedy allergy symptoms and that is how they feel. Indeed, they truly went on holiday and brought home no souvenirs, except... except...
Hour two of Larry Conners USA begins with news and commentary. He further addresses the rise in inflation as Senator Cruz offers his opinion on how the democrats have been weaponizing and scaring the public into the future of failing dems. Later, Larry offers more insight on the border crisis as over 400 unvetted Afghans [...] The post Weaponizing FBI — or FIB? / 2PM LC-USA 09-13-22 appeared first on Larry Conners USA.
Canelo Alvarez ya espera a GGG!Golovkin sentencia que él hablara en el ring!Andy Ruiz sufre de mas para vencer al veterano Luis OrtizJuan Fco Estrada se lleva una importante victoria sobre Argi Cortes y ya espera a chocolatito Gonzalez!Isaac Pitbull Cruz cumple con el tramite y pide revancha a Gervonta!
Esta semana tenemos con nosotros a la campeona del mundo FIB, De Costa Rica para el mundo Yokasta Valle. Cuando exactamente hoy jueves escuchas este podcast Yokasta va en busca de historia y su sueno que es ser doble campeona del mundo. Por primera ves en la historia llega a tierras ticas una pelea de unificación mundial. Hablamos de su preparación en su campamento en los Ángeles . De sus inicios en el box, entre otros temas mas. REDES Desde La Linea Podcast https://linktr.ee/DesdeLaLineaPod Yokasta Valle @yokavalle_oficial ''IG'' www.yoka.cr Melo @melolmr ''IG''
A classic FIB episode from 1-10-22.JK Simmons looks to be on HGH during his possible Oscar campaign…Sylvester Stallone's HGH and testosterone prevails…Alec Baldwin still holding onto his cell phone…Chris Noth's wife walks out.
On this episode of the Friends in Beauty podcast I welcome JD Barnes to the Friends in Beauty guest chair. JD is a photographer who, although having lost complete vision in his right eye due to uveitis, takes pride in his ability to see beyond the typical and in doing so create something special every time he picks up his camera. After returning to the states from a modeling career in Europe JD decided to pursue photography. With over 10 years of experience in the industry he has solidified a name for himself. His work has been featured in publications such as Essence, Harper's Bazaar, WWD, and Vogue UK to name a few. While he has photographed some of the most famous artists of today — Lizzo, Billy Porter, Regina King, Alicia Keys — he's as ambitious as ever and still pushing forward on his artistic journey. JD believes "An artist walks by feeling, by emotion, by intuition. It's what separates us from the technicians of the world. There is no fear of wrong, only of mediocrity." I was so honored to sit down and have this conversation with JD as he is someone who is very low-key & doesn't typically do interviews. My persistence paid off and I was able to get him on the FIB Podcast. I've been following his work for years and I knew that this conversation would be a treat for my photographers and other Friends in Beauty. In this interview JD shares: -How he got his start as a photographer -How his past as a model helps him as a photographer -How losing vision in his right eye affected his photography -Some pet peeves he has -How photographers can strengthen their skillset -Answers questions from the FIB community -How to protect your images from getting lost -And so much more I really enjoyed this conversation with JD and I know you will too. Let's go ahead and jump into this chat and if you prefer to watch this interview then tune in on YouTube. Enjoy this episode! Leave us a 5 star review and share this episode with a friend or 2 or 3. email@example.com FRIENDS IN BEAUTY FACEBOOK COMMUNITY www.facebook.com/groups/friendsinbeauty FOLLOW FRIENDS IN BEAUTY ON IG www.instagram.com/friendsinbeauty SUBSCRIBE TO YOUTUBE CHANNEL bit.ly/FIBTube SEND ME A TEXT! (202) 519-4652 JOIN PATREON TO SUPPORT THE FRIENDS IN BEAUTY PODCAST https://www.patreon.com/friendsinbeauty ADVERTISE YOUR BUSINESS OF THE PODCAST https://www.friendsinbeauty.com/fibadrequest Resources Mentioned In This Episode: Additional Resources: -https://www.amazon.com/shop/akuarobinson -Skillshare - Use this link for 2 months free of the premium plan: https://skl.sh/30t352q -Shop Mented Cosmetics - https://www.mentedcosmetics.com/?rfsn=1290937.f2481 Use Code “AKUAROBINSON” for 10% of your purchase Announcements: We're on Apple Podcasts - www.bit.ly/FIBPodItunes! Join our Facebook community… If you're looking for a community of like minded, ambitious, and supportive #FriendsinBeauty all working to leave our mark on the beauty industry, join us here: https://www.facebook.com/groups/friendsinbeauty Join the Friends in Beauty Mailing List: www.bit.ly/FIBTribe Social Media Info: JD Barnes (Instagram) - @jdthecombo JD Barnes (Website) - www.thejamesbarnes.com Friends in Beauty (Instagram, Facebook, Twitter) - @friendsinbeauty Friends in Beauty (YouTube) - Friends in Beauty https://www.youtube.com/channel/UCcYPyO8nAosEmjEE5nza9Zg?view_as=subscriber Akua Robinson (Instagram,Twitter) - @akuarobinson AkuaRobinson (Facebook) - Akua Robinson MUA Akua Robinson (Website) - www.akuarobinson.com
Darío Adanti hoy viene acompañado de su amigo Aldo Linares, conocido tanto por su faceta de DJ en el FIB como por ser periodista de lo paranormal y “sensitivo”. Aldo estuvo en la fundación del festival de música independiente de Bennicàssim y como "sensitivo" se ha hecho muy popular en televisión por su participación en el programa Cuarto Milenio.
A fib is most definitely a lie. A little lie. A white lie. But it's a slippery slope as Gabi and Joanne conclude on this episode of All the F Words. Who lies the most? Why do we lie? And with the proliferation of social media, are we lying more than ever? You may be surprised at what the studies show. We were surprised at how many studies on lying are being funded. And that's the truth.Follow us on social media @allthefwordspodWrite to us! firstname.lastname@example.orgNew research shows most people are honest — except for a few by Shannon Thomason https://www.uab.edu/news/research/item/12398-new-research-shows-most-people-are-honest-except-for-a-few9 Things You Should Know About Liars By Vanessa Van Edwardshttps://www.scienceofpeople.com/9-things-know-liars/Deception & Trust in Social Media and Beyond with Jeffrey Hancockhttps://www.youtube.com/watch?v=rFV5S0GI_9UAre people lying more since the rise of social media and smartphones?By David Markowitz https://theconversation.com/are-people-lying-more-since-the-rise-of-social-media-and-smartphones-170609
Šajās dienās paiet gads, kopš rietumvalstu koalīcijas spēki pameta Afganistānu un šī valsts pārsteidzoši strauji nonāca radikālā islāma kustības “Taliban” kontrolē. Amerikas Savienoto Valstu Federālās izmeklēšanas biroja darbinieki ieradušies ar kratīšanas orderi eksprezidenta Donalda Trampa rezidencē. Savukārt 12. augustā notikušais uzbrukums rakstniekam Salmanam Rušdi no jauna aktualizējis radikālā islāma terorisma problemātiku, liekot uzdot jautājumus par Irānas un vairāku citu valstu iespējamo saistību ar šiem draudiem. Ārvalstu aktualitātes pārrunājam kopā ar Latvijas Ārpolitikas institūta (LĀI) pētnieci Sintiju Broku un LĀI asociēto pētnieku Gintu Jegermani. FIB interese par eksprezidentu Trampu Pagājušās nedēļas sākumā mediji izplatīja ziņu, ka Savienoto Valstu Federālās izmeklēšanas biroja darbinieki ieradušies ar kratīšanas orderi eksprezidenta Donalda Trampa rezidencē Palmbīčā, Floridā. Kratīšanā izņemti 11 slepenu dokumentu komplekti, no kuriem daži marķēti kā „sensitīva iedalījuma informācija” – marķējums, kas norāda, ka šādas informācijas publiskošana nodarītu nopietnu kaitējumu valsts interesēm. Izņemtie dokumenti ir tapuši laikā, kad Donalds Tramps bija Savienoto Valstu prezidents, un, saskaņā ar likumu, tie bija vai nu jāiznīcina, vai jānodod Nacionālā arhīva glabāšanā. Dienu vēlāk Savienoto Valstu Tieslietu departaments publiskoja kratīšanas ordera saturu, kas atklāj, ka pret eksprezidentu uzsāktā izmeklēšana saistīta ar iespējamu nelikumīgu federālās iestādes dokumentu pārvietošanu vai iznīcināšanu, federālās izmeklēšanas materiālu falsifikāciju vai iznīcināšanu un ar Savienoto Valstu aizsardzību saistītas informācijas vākšanu, nodošanu vai nozaudēšanu, pārkāpjot t.s. Spiegošanas aktu. Tomēr Tieslietu departaments atteicies publiskot dokumentu, kuru izmeklētāji iesnieguši tiesnesim kratīšanas ordera saņemšanai, jo šādas informācijas publiskošana nopietni kaitētu izmeklēšanas procesam. Pats Donalds Tramps jau apgalvojis, ka šī izmeklēšana esot radikālo demokrātu un viņa potenciālo politisko oponentu inspirēts uzbrukums. Šobrīd tieslietu ekspertu domas dalās par to, vai potenciālās apsūdzības varētu liegt Trampam balotēties 2024. gada prezidenta vēlēšanās. Kā izriet no raksta, kurā žurnālistikas kompānija Politico atspoguļojusi situāciju Baltajā namā, kad to 2021. gada sākumā pameta Trampa administrācija, šai procesā valdījis tāds haoss, bezatbildība un noteikumu ignorēšana, ka minētie dokumenti eksprezidenta privātmājā varējuši nonākt bez īpaša nolūka. Afganistāna – gads ar talibiem Apritējis gads, kopš rietumvalstu koalīcijas spēki pameta Afganistānu un šī valsts pārsteidzoši strauji nonāca radikālā islāma kustības Taliban kontrolē. Tika pasludināta Afganistānas Islāma emirāta izveide, ar islāma teologu Haibatullu Ahunzada kā valsts galvu un mullu Hasanu Ahundu kā valdības vadītāju. Šī, kā zināms, ir jau otrā reize, kad talibi sagrābj varu Afganistānā. Pirmajā savas valdīšanas posmā viņi šeit izveidoja radikālu islāmisku režīmu, pakļaujot afgāņu dzīvi striktām normām un aizliegumiem, sevišķi krasi ierobežojot sieviešu tiesības. Šajā reizē kustības līderi solīja sievietēm atstāt vairāk brīvības, neieviest profesiju un izglītības aizliegumu, tomēr gads, kuru Afganistāna pavadījusi viņu varā, šos solījumus īsti neapstiprina. Sievietēm ir ieviestas striktas apģērba normas un prasība publiskās vietās atrasties tikai vīriešu dzimuma radinieka pavadībā. Pamatskolas izglītība meitenēm gan ir nodrošināta, taču vidējā izglītība nē, varas pārstāvjiem to skaidrojot ar organizatoriskām grūtībām. Ir zināms, ka daudzas sievietes, kuras atļāvušās publiski protestēt pret ierobežotajām izglītības iespējām, pakļautas vajāšanām un spīdzināšanai. Arī sieviešu dalība darba tirgū šī gada laikā sarukusi no 22% līdz 15%. Rietumvalstīm krasi samazinot palīdzību Afganistānai un iesaldējot tās ārvalstu valūtas rezerves, valsts ekonomika piedzīvojusi strauju kritumu par 30 – 40%. Iedzīvotāju situāciju vēl vairāk pasliktina globālais pārtikas un energoresursu cenu kāpums. Starptautiski Afganistāna joprojām paliek izolēta, un neviena pasaules valsts joprojām nav oficiāli atzinusi jaunizveidoto „emirātu”. Maz cerību, ka tuvākajā laikā šai ziņā kas varētu būtiski mainīties. Jūlijā amerikāņu drona triecienā Kabulā tika nogalināts viens no kustības Al-Qaeda līderiem Aimans al-Zavahiri, un Savienotās Valstis norādījušas, ka viņa atrašanās Afganistānas galvaspilsētā ir pretrunā ar vienošanos starp talibiem un Savienotajām Valstīm, pēc kuras noslēgšanas notika rietumvalstu karaspēka izvešana no Afganistānas. Toties diplomātiskos sakarus ar talibu režīmu ir iedibinājušās vairākas islāma valstis, arī Ķīna un Krievija. Lai gan talibu pārvaldītā Afganistāna ir problemātisks partneris jebkurai valstij, tomēr Maskava, Pekina un arī Teherāna, iespējams, mēģinās izspēlēt „talibu kārti” savā pretstāvē ar Savienotajām Valstīm. Vai Allāhs joprojām grib rakstnieka nāvi? 12. augusta priekšpusdienā Indijā dzimušais britu prozaiķis Salmans Rušdi grasījās uzstāties ar publisku lekciju Čatokvas institūtā, Savienoto Valstu Ņujorkas štatā. Neilgi pirms uzstāšanās sākuma uz skatuves uzskrēja 24 gadus vecais libāniešu izcelsmes amerikānis Hadi Matars un uzbruka rakstniekam ar nazi, desmit reizes sadurot viņu kaklā un vēderā. Uzbrucējs uz vietas tika aizturēts, Salmanam Rušdi izdevās operatīvi sniegt pirmo palīdzību un nogādāt viņu slimnīcā, un pēc pēdējām ziņām viņa stāvoklis ir sācis uzlaboties, lai gan atlabšanas process, pēc ārstu teiktā, nebūšot ātrs un viegls. Kas attiecas uz uzbrukuma motīviem, tie pagaidām nav nepārprotami zināmi, tomēr nākas pieņemt, ka Hadi Mataru slepkavības mēģinājumam iedvesmojis Irānas Islāma republikas kādreizējā garīgā līdera Homeini savulaik paustais aicinājums izrēķināties ar Salmanu Rušdi. Iemesls ir 1988. gadā publicētais romāns „Sātaniskās vārsmas”, kura sižetā var saskatīt islāma nozīmīgākā pravieša Muhameda zaimošanu. Romāna publicēšanai sekoja ajatollas Homeini izdota fetva – īpašs islāma garīgās autoritātes edikts, kas šajā gadījumā uzliek par pienākumu nogalināt romāna autoru un ikvienu, kurš būtu kā saistīts ar šī teksta izplatīšanu. Ar islāma republikas valdību saistīts fonds izsludināja trīs miljonu dolāru godalgu par Rušdi noslepkavošanu. Nākamo desmitgadi pēc fetvas izdošanas rakstnieks dzīvoja policijas apsardzībā un praktiski neparādījās publiski, tikmēr vairāki ar „Sātanisko vārsmu” izdošanu saistīti cilvēki piedzīvoja uzbrukumus; 1991. gadā romāna tulkotājs japāņu valodā Hitoši Igaraši tika nodurts. Turpmākajās desmitgadēs Irānas valdība gan vairakkārt dinstancējusies no aicinājumiem izrēķināties ar Salmanu Rušdi, tomēr vēl 2017. gadā pašreizējais Irānas garīgais līderis Ali Hamenei apliecināja, ka viņa priekšgājēja izdotā fetva joprojām ir spēkā. Zīmīgi, ka rakstnieku sadūrušā Hadi Matara ģimene savulaik ieradās Amerikā no Libānas rajona, kura iedzīvotāji savā vairumā atbalsta ar Irānu saistīto šiītu militāro grupējumu Hezbollah [hezbollā]; viņa tēvs pirms vairākiem gadiem atgriezās dzimtenē, kur pie viņa viesojies arī Hadi. Uzbrukums Salmanam Rušdi no jauna aktualizējis radikālā islāma terorisma problemātiku, liekot uzdot jautājumus par Irānas un vairāku citu valstu iespējamo saistību ar šiem draudiem. Sagatavoja: Eduards Liniņš. Eiropas Parlamenta granta projekta „Jaunā Eiropas nākotne” programma.* * Šī publikācija atspoguļo tikai materiāla veidošanā iesaistīto pušu viedokli. Eiropas Parlaments nav atbildīgs par tajā ietvertās informācijas jebkādu izmantošanu.
Calcium is one of the ions that move across the cellular membrane during cardiac contraction and relaxation. For ACLS, the primary use of calcium channel blockers is for the treatment of stable, narrow complex tachycardias refractory to vagal maneuvers and Adenosine. Nicardipine may also be used to lower the blood pressure of ischemic stroke patients with severe hypertension. Use of calcium channel blockers for SVT refractory to Adenosine and A-Fib or A-Flutter with RVR. Contraindications of calcium channel blockers. Nicardipine's use during the treatment of ischemic strokes. Connect with me: Website: https://passacls.com (https://passacls.com) https://twitter.com/PassACLS (@PassACLS) on Twitter https://www.linkedin.com/company/pass-acls-podcast/ (@Pass-ACLS-Podcast) on LinkedIn Good luck with your ACLS class!
In atrial fibrillation (A-Fib) and atrial flutter (A-Flutter) the electrical impulse for cardiac contraction is in the atria but isn't the normal pacemaker of the heart, the SA node. The ECG characteristics of A-Fib and A-Flutter. Recognition and treatment of unstable patients in A-Fib/Flutter with rapid ventricular response (RVR). Team safety when cardioverting a patient in A-FIB with RVR. Treatment of stable patients in A-Fib/Flutter with RVR. Connect with me: Website: https://passacls.com (https://passacls.com) https://twitter.com/PassACLS (@PassACLS) on Twitter https://www.linkedin.com/company/pass-acls-podcast/ (@Pass-ACLS-Podcast) on LinkedIn Good luck with your ACLS class!
As the NASH pandemic grows in the number and diversity of patient cases, one patient group receiving increased notice includes patients with "lean NASH," those whose BMI levels are "normal." Last month, Gastroenterology published Best Practice recommendations for diagnosing and treating lean NASH. Two of the authors, Drs. Michelle Long and Mazen Noureddin, were good enough to come on the podcast to share the thinking behind this article along with its key observations and recommendations.This conversation starts with Roger Green asking Michelle and Mazen how they came to write this piece and how the paper came together working with co-author, Dr. Joseph Lim. First, as Michelle notes, "we had to all get on the same page," on the issue of the highest BMI that would be considered lean or, more precisely, not overweight. From there, the team outlined 15 Best Practices based on clinical experience, and set out to refine these based on relevant literature and recommendations from colleagues and reviewers. The co-authors note that while little of what they learned while preparing this paper was surprising, it forced them to focus on creating a fairly simple set of stepwise goals for clinicians to follow. Louise Campbell joins the conversation to praise the simplicity and clarity of the Best Practices chart the co-authors created. After noting that this algorithm is not very different from others, Mazen goes on to mention "a couple of things...that we're proud of:" identification of high-risk patients based on age (over 40) or presence of Type 2 diabetes. He also notes that they provided greater clarity around more advanced non-invasive tests like ELF, MAST, FAST, MEFIB, MRI, and cT1.The conversation shifts to focus on the recommendation to retest every 6 or 12 months. Louise notes this approvingly. The group agrees that screening T2D patients annually using FIB-4 is not very different than screening annually for eye, kidney or neurological complications. Roger Green joins the conversation to suggest a 3-5 year follow-up recommendation is not patient-centric, but might calm payers concerned about skyrocketing costs of treating Fatty Liver disease. Mazen shares his expectation that yearly evaluation will be cost-effective and patient-centric. Roger shares an informal belief he has developed that whether due to later stage diagnoses or different disease pathogenesis, lean NASH patients might be more costly because patients progress to cirrhosis more quickly after the original diagnosis. Michelle tends to agree but notes that more research is needed on this.Next, the conversation shifts toward diagnostic approaches. Roger mentions the possible benefit of the "Fibrosis First" method that Ian Rowe discussed the previous week (S3, E39), particularly appropriate when primary care providers observe danger signs in lean patients. Mazen points to extremely elevated liver enzyme levels (ALT of 80 or 90). Michelle agrees, but notes that most of her lean NASH patients are diagnosed in an ED with complications of cirrhosis. The group then spends time asking what might make primary care providers comfortable testing for fibrosis, even if only to pass the patient on to the appropriate specialist. Roger asks what different groups can learn from this paper. Michelle states that this is a clear call for more research. Mazen points to Table 2 in the paper, which lists other diseases that hepatologists should consider when evaluating these patients. He continues to state that the document is helpful for non-hepatologists and hepatologists alike. Finally, he points out that clinical trials are pivotal for these patients. The last several moments focus on how to ask patients about alcohol consumption and then the closing question. Michelle notes the importance of using lists and tables in the paper to guide the special issues in treating these patients.
A 40 AÑOS DE SU MUERTE RECORDAMOS A SALVADOR SANCHEZ!!VERGIL ORTIZ CUMPLE EL TRAMITE Y VENCE A MCKINSON!TEOFIMO LOPEZ REGRESA TRAS DERROTA ANTE KAMBOSOS!!PEDRO CAMPA BUSCA DAR LA CAMPNADA ANTE TEO LOPEZ!!OMAR FIGUEROA JR. ACEPTA QUE LOS PROBLEMAS PERSONALES LE PERJUDICARON!!
One serious challenge in the overall management of Fatty Liver disease involves creating cost-effective methods for "early" diagnosis. The term "early" is relative because, as Ian Rowe puts it, a "substantial proportion" of people admitted to hospital with various symptoms of decompensating cirrhosis or hepatic encephalopathy never received a diagnosis of advanced liver disease before they presented. Simply diagnosing these patients during advanced fibrosis (F2 or F3) can save lives, improve longevity and quality of life for these patients and save money for healthcare systems, all at the same time. Ian spends the first ten minutes of this episode describing a model he and Richard Parker developed to evaluate five diagnostic strategies:Targeted -- simple non-invasive liver screening Targeted + risk stratification -- targeted assessment plus FIB-4 or VCTE (FibroScan) for patients believed to be at high riskiLFT -- automated assessment of abnormal LFTs analyzed with other systemic measures in a medical record system "Comprehensive" -- a "kitchen sink" approach that runs iLFT analysis and conducts FIB-4 +/- VCTE on every patient"Fibrosis first" -- an approach that deploys viroserological and iron testing plus FIB-4 +/- VCTE for every patient "Fibrosis first" scored best in cost effectiveness (cost per correct diagnosis of treatable liver disease) and "decision curve analysis", which looks at true positive outcomes and false positive outcomes, correctly identifying 85% of treatable liver disease patients (vs. 90% for the comprehensive approach and less than 15% for the current targeted approach.) Fibrosis first has the added benefit of not progressing treatment for people who may have steatosis without fibrosis. The rest of the conversation entails Ian, Louise Campbell and Roger Green sharing questions and observations. Highlights:Louise agrees that the current targeted pathway approaches do not work and identifies lack of access to advanced testing in primary care as a central issue. She asks how many additional patients with Type 2 Diabetes, other metabolic diseases or CVD could be identified through this approach. Ian cannot answer because the question is outside the scope of the research. He points out that to assess different approaches accurately, researchers and policymakers need to settle on whether the goal is to identify steatohepatitis or something broader. Louise asks about the frequency and nature of referrals. Ian notes that one issue with iLFT is a high level of referrals for conditions that might not require treatment, the most common of which is "abnormal LFT without fibrosis."Roger notes that iLFT might help patients who complain they never heard about their NASH earlier. He also recalls Quentin Anstee and Stephen Harrison discussing recently that FIB-4 can serve as a prognostic measure not only for liver-related deaths, but also CV deaths and all-cause mortality. Louise suggests that patients will do better if they adopt a behavior belief model instead of a sick patient approach and that the earlier in disease we intervene, the more success we will have. Roger and Ian note that Louise's focus is broader in scope than his model. Ian further notes that we do not know when non-fibrotic patients should be tested again, although he has some thoughts about this. Louise notes that one element that might make iLFT costly is that only 45% of patients picked up on iLFT are referred into the model. Ian notes that this insight might require changes in the model.As the conversation winds down, it shifts toward policy issues: should we focus testing on the workforce (Louise) and it the best point of intervention to limit advertising of unhealthy foods (Ian).
This week, Surfing the NASH Tsunami returns to a subject we have explored from time to time over the past two years: helping patients with cirrhosis. While the immediate stimulus for doing so was the semaglutide late-breaker at #ILC2022, our more general interest is that many patients with cirrhosis will start to decompensate and decline in a fairly short period of time. This conversation focuses on a specific question: where is the next breakthrough in cirrhosis patient management likely to come?This conversation starts with Roger reflecting on a comment Lars had made during a previous appearance on the podcast, that we should spend more time focusing on what should be happening in the liver instead of what shouldn't. Lars notes one reason for this: when we look at other organ systems (heart or kidney, for example), we focus on how the organ functions. With the liver, we read static biopsies that do not measure actual function. He goes on to note that researchers are developing functional tests, many of which require labeled compounds and then record how they move through the body. At this point, Roger shifts the discussion by asking the panel where members anticipate the next major breakthrough in improving cirrhosis diagnosis and treatment. Louise responds first by noting the need to pick up patients earlier in the course of the disease as they move through the healthcare system. She envisions that this may come by adding. FIB-4 to every patient coming through the system or perhaps to something like the iLFT that John Dillon described at the Barcelona meeting. Even there, she notes, the system picks up only 50% of diseased patients. Jörn describes the need to improve diagnostic performance, both in terms of better tests and better ability to deliver both testing and results to patients. Lars questions whether the answer lies in providing imaging tests for every patient. Instead, he suggests, we need to link imaging results more closely to liquid biomarkers and then drive universal, early use of these less expensive liquid tests. As the conversation ends, Louise agrees with this point but notes again that we are assuming a level of patient communication and provider follow-through that does not exist today.
Lugha ya Kiswahili hivi sasa ni lugha ya kimataifa ikiwa imetengewa siku yake mahsusi ya kuadhimishwa ambayo ni tarehe 7 Julai kila mwaka. Wakati wa maadhimisho ya mwaka huu, Mkurugenzi Mkuu wa shirika la Umoja wa Mataifa la elimu, sayansi na utamaduni, UNESCO, Audrey Azoulay alisema uamuzi wa Baraza Kuu la UNESCO kutambua lugha ya kiswahili kimataifa ulizingatia mambo kadhaa ya msingi ikiwemo nafasi ya lugha hiyo katika kusongesha amani. Na hilo linafanyika tayari huko Jamhuri ya Kidemokrasia ya Congo, DRC kama anavyoelezea Kamanda wa Kikundi cha tisa cha walinda amani kutoka Tanzania, TANZBATT-9 kinachohudumu kwenye kikosi cha kujibu mashambulizi, FIB chini ya ujumbe wa Umoja wa Mataifa wa kulinda amani nchini DRC, MONUSCO. Kamanda anaanza kwa kujitambulisha katika makala hii iliyofanikishwa na Denisia Lihaya wa TANZBATT-9 na kusimuliwa na Assumpta Massoi.
Patients with a narrow complex tachycardia with a rate over 150 BPM are in SVT. Unstable patients in SVT or A-Fib/Flutter with RVR should be cardioverted with a synchronized shock. Stable patients should have an IV established, oxygen if the SaO2 is less than 90%, and a 12 lead ECG before attempting vagal stimulation. Commonly used vagal techniques. Less common techniques include stimulation of the dive reflex and carotid sinus massage (if within your scope of practice). The use of Adenosine for stable patients in SVT refractory to vagal maneuvers. For patients found to be in A-Fib or A-Flutter with RVR we should consider use of a calcium channel blocker or beta blocker. Connect with me: Website: https://passacls.com (https://passacls.com) https://twitter.com/PassACLS (@PassACLS) on Twitter https://www.linkedin.com/company/pass-acls-podcast/ (@Pass-ACLS-Podcast) on LinkedIn Good luck with your ACLS class!
Empezamos descubriendo todas las caras de Caetano Veloso de la mano de nuestro compañero Carlos Galilea, autor del que, probablemente, es el libro más completo y original que se ha publicado sobre el músico brasileño en nuestro país. Y de ahí, directos a Benicàssim donde, tras un parón de dos años, el FIB vuelve a abrir sus puertas. Además, descubriremos cómo Monica Bellucci devuelve a la vida a Maria Callas en el Festival de Peralada. Escuchar audio
Today on the Friends in Beauty Podcast I'm sharing some ways that you can support the Friends in Beauty Podcast for FREE.99 and some new and exciting things that I have added to the FIB umbrella. But what I really want to talk about is why most of my #friendsinbeauty and other entrepreneurs are not achieving the success and the results that they want. It's because you have to DO THE WORK! When are you actually going to implement the information that you learn? I share with you how I've been doing the work and hopefully it will light a fire under you to do the same. Let's get to it! Don't forget to share with another #FriendinBeauty Enjoy this episode! Leave us a 5 star review and share this episode with a friend or 2 or 3. email@example.com Resources Mentioned In This Episode: FRIENDS IN BEAUTY FACEBOOK COMMUNITY www.facebook.com/groups/friendsinbeauty FOLLOW FRIENDS IN BEAUTY ON IG www.instagram.com/friendsinbeauty SUBSCRIBE TO YOUTUBE CHANNEL bit.ly/FIBTube SEND ME A TEXT! (202) 519-4652 JOIN PATREON TO SUPPORT THE FRIENDS IN BEAUTY PODCAST https://www.patreon.com/friendsinbeauty ADVERTISE YOUR BUSINESS OF THE PODCAST https://www.friendsinbeauty.com/fibadrequest ENROLL IN THE FRIENDS WITH BENEFIT$ CLUB https://friends-with-benefits.teachable.com/p/friends-with-benefits-club PODCAST EDITING 101 CLASS bit.ly/PodcastEditing101 Additional Resources: -https://www.amazon.com/shop/akuarobinson -Skillshare - Use this link for 2 months free of the premium plan: https://skl.sh/30t352q -Shop Mented Cosmetics - https://www.mentedcosmetics.com/?rfsn=1290937.f2481 Use Code “AKUAROBINSON” for 10% of your purchase Announcements: We're on Apple Podcasts - www.bit.ly/FIBPodItunes! Join our Facebook community… If you're looking for a community of like minded, ambitious, and supportive #FriendsinBeauty all working to leave our mark on the beauty industry, join us here: https://www.facebook.com/groups/friendsinbeauty Join the Friends in Beauty Mailing List: www.bit.ly/FIBTribe Social Media Info: Friends in Beauty (Instagram, Facebook, Twitter) - @friendsinbeauty Friends in Beauty (YouTube) - Friends in Beauty https://www.youtube.com/channel/UCcYPyO8nAosEmjEE5nza9Zg?view_as=subscriber Akua Robinson (Instagram,Twitter) - @akuarobinson AkuaRobinson (Facebook) - Akua Robinson MUA Akua Robinson (Website) - www.akuarobinson.com
Adenosine is indicated for the treatment of stable, narrow-complex supraventricular tachycardia refractory to vagal maneuvers. Review the actions of Adenosine on the SA and AV node of the heart. Contraindications and precautions for use of Adenosine, Adenosine dosing and administration. Adenosine's use in identifying A-Fib or flutter with RVR. Adenosine may be considered for patients with monomorphic wide-complex tachycardias. Connect with me: Website: https://passacls.com (https://passacls.com) https://twitter.com/PassACLS (@PassACLS) on Twitter https://www.linkedin.com/company/pass-acls-podcast/ (@Pass-ACLS-Podcast) on LinkedIn Good luck with your ACLS class!
Last month, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022.) On Thursday afternoon, Scott Friedman chaired an abstract session discussing advances in the basic science of researching and understanding mechanisms surrounding fibrosis and stellate cells. Later, he described it as "one of the most exciting groups of presentations I've seen in many years." The conversation starts with Roger Green asking the panel how to pay this research off in terms of commercial benefit. Most of the conversation consists of their answers.Scott Friedman answers Roger's question first. He notes that these advanced techniques will allow us to focus on not only the right type of cell but the right subtype(s). Hitting the right target dead-on will improve the efficacy of drugs and the accuracy of diagnostics. Also important (perhaps more so): we can avoid what Scott calls "off-target effects", which commercial executives might think of as safety, tolerability and side effect issues. Consistent with other themes NASH Tsunami visits regularly, Jörn notes that the future of therapy is likely to be individualized, multi-element, and probably multi-phase. The more this basic research can teach us about the disease process stages and how they vary by patient, the better job drug developers can do in developing medicines that resolve specific patients' needs. Scott notes that if we can hypothesize which patients will respond best to a specific intervention, we can streamline clinical trials, possibly reduce sample sizes, separate respondents from non-responders better and/or shorten trial durations. All these possible outcomes stem from the increasingly demonstrable reality that NAFLD or NASH is actually a set of related diseases rather than a single, uniform disease process.As the session begins to wind down, Roger invites Scott to discuss any other topics that emerged from the abstract session. Scott mentions the last paper in the session, where researchers from Heidelberg explored a specific receptor whose acronym is RAGE (Receptor for Advanced Glycation End-products). RAGE drives what Scott terms "a very important response," seen both in NASH and cholestatic disease, in which bile ducts proliferate. This is called a ductular reaction. As Scott notes, both the cause of this reaction and its relationship to fibrosis have been "a bit hazy." Now, this group has identified some players that might be involved in this process...and identified them in such a way that therapeutics are being developed against RAGE. This will benefit NASH and, even more clearly, cholestatic diseases.As the last question before wrapping up, Roger asks the rest of the panel if they have comments about the meeting aside from this session. Neil points to the optimism and energy caused not only by the new methods but also by the sharing of knowledge AND larger data sets, all of which can lead to molecular pathology-based approaches that will help us define the multiple diseases in the NAFLD galaxy better. Jörn goes almost to the other extreme, commenting on presentations demonstrating the value of FIB-4 as a first-line screening tool and others challenging FIB-4 the same way. To Jörn, this identifies the need for a better first-line screening test, which the kinds of research covered in this session might produce. Roger closes the conversation by noting that the two outstanding benefits of FIB-4 are its low cost and wide availability, which suggests the next steps we are more likely to see is a staged approach to diagnosis and screening.
Last week, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first major hepatology Congress to be held in person since the start of the pandemic (smaller, but very valuable, meetings like NASH-TAG, LiverCONNECT and Paris NASH have taken place with an in-person component, but the International Liver Congress and The Liver Meeting have not). The first three days of the program focused on a range of issues, with specific emphasis on non-invasive tests (NITs) and their role at different stages in diagnosis and treatment. This conversation touches on two issues: how proper use and explanation of NITs can increase patient motivation and why adding NITs to quality measures can have such an effect on educating providers and increasing treatment.This conversation starts with Michelle Long and Louise Campbell discussing studies that demonstrated that patients receiving a FibroScan changed behaviors in ways that lasted at least six months, whether or not they learned they had liver fat. From here, Zobair Younossi discusses the importance of front-line, primary care screening with FIB-4 for all patients with diabetes. Zobair suggests that we consider making use of FIB-4 as a test for co-morbidities in diabetes a formal quality measure, in the same way that providers are required to check creatinine to assess possible kidney damage. Michelle and Roger Green added to Zobair's comment to discuss the specific benefits of adding an electronic health record-generated FIB-4 test as a standard assessment for diabetic patients. Zobair goes back to the point that we need primary care to serve as a front line for diabetes testing. In this context, he suggests the importance of FIB-4 and gives reasons he believes FibroScan will never become widely used in primary care. Louise Campbell disagreed, saying that having FibroScan in primary care would educate patients and drive better care. Jörn Schattenberg discusses some sessions where the consensus supported early FIB-4 use. Roger Green wraps up this conversation by talking about the importance of having formal quality measures around FIB-4 use in the US by telling a story from his own medical history.
During last week's #ILC2022 meeting in London, Louise Campbell took the opportunity to sit down with PBC Foundation CEO and Fatty Liver patient Robert Mitchell-Thain to discuss patient engagement from their own perspectives, Louise as a longtime hepatology nurse (and NAFLD nurse) and Robert as a patient advocate and NAFLD patient.In this conversation, Louise and Robert start by discussing items that have "rocked their world" from this meeting. Robert starts by commenting on presentations that suggest how many patients get missed with a FIB-4 or ALT and expresses the hope that we will improve screening processes to find more people quickly. From there, the conversation shifts toward the role of stigma in patient communication. Specifically, Robert notes about "internal" stigma, the discomfort that patients have discussing their own issues of weight and appearance or sexual dysfunction. Specifically, he states that patients need to "lead from the front" by bringing the statements out in the open, which will make it more obvious that physicians and nurses need to raise these issues during initial visits. It will also push these issues into clinical trials, where we can learn about frequency. Robert notes that nurses have unique value: physicians care about metrics and medical numbers, patients care about quality-of-life, and nurses has the knowledge and skills to bridge between the two. In closing, both agree that patients need to be bold and up-front about their issues instead of, as Louise notes, surrending all accountability once a person allows herself to be define as a patient.
Más Derroteros con Santiago Alba Rico Llega el estío y nos vamos de festivales con el PLANAZO del Sr. Sanabria: hablamos del poder de la música, de festivales y experiencias transformadoras. De los 25 años del FIB con “Aquí Vivía Yo”, las memorias de los 25 años que Joan Vich Montaner pasó al frente del Festival Internacional de Benicassim. También nos acordamos del Azkena Rock Festival, el festival rockero de Vitoria, que celebra su vigésimo aniversario, y en el que toca nuestra banda invitada, Tiburona. Más información aquí: https://bit.ly/PlanazoFestisCC1067 Haz posible Carne Cruda: http://bit.ly/ProduceCC